# Novo nordisk — media coverage

Novo nordisk was mentioned 46 times in 23 outlets across 9 countries over the last 12 months. 26% of that coverage was positive and 11% negative. 85% was editorial rather than PR or paid placement.

- Data as of: 2026-10-04 (window: last 365 days)
- Mentions (12 months): 46 (48 all-time)
- Outlets (12 months): 23 in 9 countries
- Average sentiment: +0.124 (26% positive, 11% negative)
- PR / editorial: 7 PR · 39 editorial
- Sector: Pharma

## Coverage over time (mentions per month)

| Month | Mentions |
|---|---|
| 2025-11 | 0 |
| 2025-12 | 0 |
| 2026-01 | 1 |
| 2026-02 | 1 |
| 2026-03 | 0 |
| 2026-04 | 0 |
| 2026-05 | 0 |
| 2026-06 | 17 |
| 2026-07 | 0 |
| 2026-08 | 26 |
| 2026-09 | 1 |
| 2026-10 | 0 |

## Top outlets (12 months)

| Outlet | Mentions |
|---|---|
|  | 17 |
| finance.yahoo.com | 3 |
| foreignpolicyjournal.com | 3 |
| ad-hoc-news.de | 2 |
| stocktitan.net | 2 |
| tradingview.com | 2 |
| 6abc.com | 1 |
| altonivel.com.mx | 1 |

## Countries (12 months)

| Country | Mentions |
|---|---|
| INT | 19 |
| US | 19 |
| DE | 2 |
| AT | 1 |
| AU | 1 |
| CA | 1 |
| GB | 1 |
| IN | 1 |
| MX | 1 |

## Languages (12 months)

| Language | Mentions |
|---|---|
|  | 45 |
| de | 1 |

## Share of voice among Pharma peers (12 months)

| Brand | Mentions |
|---|---|
| Eli lilly | 130 |
| Astrazeneca | 78 |
| Pfizer | 64 |
| Johnson & johnson | 59 |
| Novo nordisk | 46 |
| Merck | 44 |
| Sandoz | 41 |
| Moderna | 38 |
| Bayer | 36 |
| Roche | 36 |

## Recent coverage

- [Eli Lilly’s diabetes drug Mounjaro approved to reduce cardiovascular risks - Business Today](https://www.businesstoday.in/industry/pharma/story/eli-lillys-diabetes-drug-mounjaro-approved-to-reduce-cardiovascular-risks-552305-2026-09-01) — businesstoday.in, 2026-09-01, neutral
- [Novo Nordisk stock consolidates as Wegovy tablet launch and buybacks reshape the obesity story - ad-hoc-news.de](https://www.ad-hoc-news.de/boerse/news/corporate-news/novo-nordisk-stock-consolidates-as-wegovy-tablet-launch-and-buybacks/70031841) — ad-hoc-news.de, 2026-08-31, neutral
- [Novo Nordisk's Chinese Filing and a 30 Million-Share Buyback: A Stock Caught Between Two Narratives - ad-hoc-news.de](https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/novo-nordisk-s-chinese-filing-and-a-30-million-share-buyback-a-stock/70031151) — ad-hoc-news.de, 2026-08-31, neutral
- [Novo Nordisk (NYSE: NVO) details progress on DKK 15B buyback - Stock Titan](https://www.stocktitan.net/sec-filings/NVO/6-k-novo-nordisk-a-s-current-report-foreign-issuer-bb8d0b6779a2.html) — stocktitan.net, 2026-08-31, neutral
- [Novo Nordisk A/S - share repurchase programme - Yahoo! Finance Canada](https://ca.finance.yahoo.com/news/novo-nordisk-share-repurchase-programme-111700288.html) — ca.finance.yahoo.com, 2026-08-31, neutral
- [Novo Nordisk expects up to DKK15B in buybacks; DKK8.71B repurchased - Stock Titan](https://www.stocktitan.net/news/NVO/novo-nordisk-a-s-share-repurchase-vrrta5hufd6e.html) — stocktitan.net, 2026-08-31, positive
- [Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy expand rivalry into cardiovascular drugs - DongA Science](https://www.dongascience.com/en/news/79679) — dongascience.com, 2026-08-31, positive
- [Weekly Recap: 77% 2025 sales patent risk and GLP-1 employer coverage drop - TradingView](https://www.tradingview.com/news/tradingview:97c9978054149:0-weekly-recap-77-2025-sales-patent-risk-and-glp-1-employer-coverage-drop/) — tradingview.com, 2026-08-31, neutral

Data: VoilàIQ, 2026-10-04. Canonical: https://voilaiq.com/brand-catalog/novo-nordisk